Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lycera Corp.

www.lycera.com

Latest From Lycera Corp.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics

Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.

M & A Deals

Appointments: Sanofi, Fosun Kite, Milestone, Tocagen, GW Pharma, Hookipa and Bone Therapeutics

This week’s round-up includes the appointment of independent directors by Sanofi’s board of directors, CEO appointments by Fosun Kite Biotechnology and Milestone Pharmaceuticals as well as executive appointments by Tocagen, GW Pharmaceuticals, Bone Therapeutics and Tris Pharma.

Appointments BioPharmaceutical

Pipeline Watch: Phase III Results With Tagrisso, Biosimilar Rituximab And Vonvendi

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lycera Corp.
  • Senior Management
  • Paul Sekhri, Pres. & CEO
    Alex G Howarth, CFO
    Gary D Glick, PhD, CSO
    Bruce Goldsmith, PhD, CBO
    H. Jeffrey Wilkins, MD, CMO
  • Contact Info
  • Lycera Corp.
    Phone: (734) 233-3060
    2800 Plymouth Rd.
    NCRC Bld 26
    Ann Arbor, MI 48109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register